Welcome to BioSeeker Group!

Prostate and Breast Cancer- New Treatments and Developmental Progress

Additional Information

Published Date Mar 1, 2007
Pages 192
PDF Fact Sheet View Fact Sheet for the report Prostate and Breast Cancer- New Treatments and Developmental Progress in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$2,950.00

Quick Overview

Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. This report present the very latest on breast and prostate cancer drug development.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Prostate and Breast Cancer- New Treatments and Developmental Progress.

    To find out more about Prostate and Breast Cancer- New Treatments and Developmental Progress, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Prostate and Breast Cancer- New Treatments and Developmental Progress is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million women in the US are living with breast cancer. Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. Newly approved drugs are showing increased sale figures, and several of them are reaching for broader indications. So, the trend of continuously increasing revenues is expected for drugs presenting reliable clinical data to support their successful progress.

Research and analysis highlights

In the report "Prostate & Breast Cancer - New Treatments & Developmental Progress" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate and breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified approximately 200 drug candidates in clinical stage of development and more than 125 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in these markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development.
  • Scientific rationale for most novel therapeutics in breast and prostate cancer R&D, and the results of clinical trials to date
  • Gain insight into the current challenges and commercial opportunities associated with breast and prostate cancer therapy
  • Two hundred high quality references

Some of the drugs included in this analysis:

4HPR, Anastrozole, Arsenic trioxide, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, DCVax-prostate, Doxorubicin, Epothilone D, Erlotinib, Exemestane, Exisulind, Fulvestrant, Gefitinib, Goserelin, GVAX, Imatinib, ixabepilone, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Oblimersen sodium, Patupilone, Pemetrexed, PTK/ZK, R-flurbiprofen, Toremifene Temsirolimus, Theratope, Tipifarnib, Trastuzumab, Satraplatin, SDX-105, sipuleucel-T, Sorafenib tosylate, Vapreotide

Some of the companies included in this analysis:

Antigenics, AstraZeneca, Bayer, Baxter International, Biomira, Bristol Myers-Squibb, Cell Genesys, Cephalon, Debiopharm, Dendreon, Eli Lilly, Encore Pharmaceuticals, Genentech, GlaxoSmithKline, Genta, GTx, Isis Pharmaceuticals, Johnson and Johnson, Kosan Biosciences, Lorus Therapeutics, Merck, Millennium Pharmaceutical, Northwest Biotherapeutics, Novartis, Orion Pharma, OSI Pharmaceuticals, NeoRx, Novartis Pharmaceuticals, Pfizer, Roche, Salmedix, Schering-Plough, Wyeth, YM BioSciences

Some of the companies included in this analysis:

Antigenics,
AstraZeneca,
Bayer,
Baxter International,
Biomira,
Bristol Myers-Squibb,
Cell Genesys,
Cephalon,
Debiopharm,
Dendreon,
Eli Lilly,
Encore Pharmaceuticals,
Genentech,
GlaxoSmithKline,
Genta,
GTx,
Isis Pharmaceuticals,
Johnson and Johnson,
Kosan Biosciences,
Lorus Therapeutics,
Merck,
Millennium Pharmaceutical,
Northwest Biotherapeutics,
Novartis,
Orion Pharma,
OSI Pharmaceuticals,
NeoRx,
Novartis Pharmaceuticals,
Pfizer,
Roche,
Salmedix,
Schering-Plough,
Wyeth,
YM BioSciences
Some of the drugs included in this analysis:

4HPR, Anastrozole, Arsenic trioxide, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, DCVax-prostate, Doxorubicin, Epothilone D, Erlotinib, Exemestane, Exisulind, Fulvestrant, Gefitinib, Goserelin, GVAX, Imatinib, ixabepilone, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Oblimersen sodium, Patupilone, Pemetrexed, PTK/ZK, R-flurbiprofen, Toremifene Temsirolimus, Theratope, Tipifarnib, Trastuzumab, Satraplatin, SDX-105, sipuleucel-T, Sorafenib tosylate, Vapreotide

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Prostate and Breast Cancer- New Treatments and Developmental Progress.
    To find out more about Prostate and Breast Cancer- New Treatments and Developmental Progress, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Prostate and Breast Cancer- New Treatments and Developmental Progress is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More


Biologicals in Oncology: Drug Pathway Analyzer
There are today at least 2306 biological drugs known to affect more than 269 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 674 drug targets that are included in this drug-pathway analyzing tool. No less than 607 of these have been recorded with mutations and 76 drug targets have mutations which have been causally implicated in cancer. Learn More